Interferon α 2b treatment for residual ocular surface squamous neoplasia unresponsive to excision, cryotherapy and mitomycin-C

Arie Y. Nemet*, Vidushi Sharma, Ross Benger

*Corresponding author for this work

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Three patients had residual or recurrent tumour following excision of large ocular surface squamous neoplasia (OSSN) lesions, which did not resolve despite the use of adjunctive cryotherapy and topical mitomycin-C therapy. The residual tumour was treated with topical or subconjunctival injectable interferon α 2b. All three eyes had complete resolution of the OSSN lesions after an average of 6 weeks (range 4-8 weeks) of treatment with interferon α 2b. No regrowth was seen during the follow-up period of 22.7 ± 32.3 months (range 5-60 months). No adverse reactions or complaints were reported during and following interferon use, and previous symptoms from mitomycin-C treatment resolved completely. In these patients subconjunctival or topical interferon was an effective and safe treatment for residual OSSN. Longer follow up is required to confirm the long-term efficacy in prevention of recurrences.

Original languageEnglish
Pages (from-to)375-377
Number of pages3
JournalClinical and Experimental Ophthalmology
Volume34
Issue number4
DOIs
Publication statusPublished - May 2006

Keywords

  • Carcinoma in situ
  • Fluorouracil
  • Interferon type II
  • Mitomycin-c

Fingerprint Dive into the research topics of 'Interferon α 2b treatment for residual ocular surface squamous neoplasia unresponsive to excision, cryotherapy and mitomycin-C'. Together they form a unique fingerprint.

Cite this